Viatris Launches $1.65B Tender Offer for Pacira at $36.50/Share; $62M Break Fee Disclosed
VTRS sits 83% above its 52-week low of $9.69.
Summary
Viatris formally launched its $1.65 billion all-cash tender offer for Pacira BioSciences at $36.50 per share, with a $62 million break fee and a no-vote second-step merger structure.
Key Events · M&A and Partnerships · VTRS
-
Tender Offer Commenced at $36.50/Share
Viatris' wholly owned subsidiary Peach Purchaser Sub Inc. will offer $36.50 per share in cash for all outstanding Pacira common stock, representing $1.65 billion in aggregate equity value.
-
No-Vote Second-Step Merger
Following the tender offer, the merger will be completed under Delaware Section 251(h) with no Pacira stockholder vote required, subject to the Minimum Condition of one share more than 50% tendered.
-
$62M Termination Fee
Pacira must pay Viatris a $62 million termination fee if the deal is terminated under specified circumstances, including entry into a superior offer or withdrawal of the board's recommendation.
-
Deal Timeline and Conditions
The offer runs for 10 business days, with an End Date of April 8, 2027, automatically extended to July 8, 2027 if only antitrust or legal-restraint conditions remain. HSR filing required within 15 business days.
Analysis · VTRS · Life Sciences
Viatris has formally commenced its all-cash tender offer for Pacira BioSciences at $36.50 per share, adding EXPAREL and ZILRETTA to its non-opioid pain portfolio. The SC TO-C filing reveals the deal's full mechanics: a 10-business-day offer, a minimum condition requiring just over 50% of shares tendered, and a no-vote second-step merger under Delaware Section 251(h). Pacira would owe a $62 million termination fee if it walks away for a superior offer. The deal is expected to close by end of 2026 and be immediately accretive to Viatris' financial guidance, funded primarily from excess cash with minimal leverage impact.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 42.9% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTRS was trading at $17.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1B. The 52-week trading range was $9.69 to $18.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.